Head to head
NovoCare Pharmacy vs Hims
Both are real, operating US telehealth companies. What separates them is what they supply, what they charge for it, and what regulators have published about each — all of it below, linked to the primary documents.
- NovoCare Pharmacy
- FDA-approved
$149/mo - Hims
- FDA-approved
$149/mo - NovoCare Pharmacy on file
- 1
- Hims on file
- 4
Side by side
What each one publishes about itself
Every figure here is the provider’s own advertised number, not an estimate. A dash means the company does not publish it.
| NovoCare Pharmacy | Hims | |
|---|---|---|
| Supplies | FDA-approved medication only | FDA-approved medication only |
| Advertised from | $149/mo | $149/mo |
| First month | $199 | $39 |
| Medication in the price | Included | Billed separately |
| Insurance | Cash pay | Cash pay |
| Intake | — | Async |
| On the record | 1 action | 4 actions |
The difference that actually matters
Supplies FDA-approved medication only — Wegovy, Zepbound, Ozempic, Mounjaro or the approved oral versions. Higher priced, and outside the compounding enforcement entirely.
What is on NovoCare Pharmacy’s record
2025-09
FDA warning letter to Novo Nordisk, Inc. (MARCS-CMS 716495) finding that the same ABC primetime special minimised and omitted risk information, creating a misleading impression regarding the safety of Wegovy, Ozempic and Victoza.
What is on Hims’s record
2025-09
FDA warning letter to Hims & Hers Health, Inc. dba Hims (MARCS-CMS 716567) over compounded GLP-1 marketing.
2026-03
Novo Nordisk sued Hims & Hers for infringement of US Patent 8,129,343 in the District of Delaware on 9 February 2026 (No. 1:26-cv-00143) and voluntarily dismissed it without prejudice on 9 March 2026, expressly reserving the right to refile, under an agreement in which Hims & Hers stopped advertising compounded GLP-1s and began distributing Novo's FDA-approved semaglutide.
2026-07
The FTC, the State of Utah and Los Angeles County sued Hims & Hers Health, Inc. in the Northern District of California under FTC Act section 5 and ROSCA, alleging the company disclosed customers' health information to advertising platforms including Meta and Snap, charged consumers before the promised provider consultation, and obstructed cancellation; allegations unproven.
Go direct
Both companies, and what we earn from each
We do not recommend one over the other. Where a link pays us, it says so here and on the provider’s own page.
NovoCare Pharmacy
FDA-approved medication only, from $149 a month. 1 action on record, each linked on its page. The link below earns us nothing.
Hims
FDA-approved medication only, from $149 a month. 4 actions on record, each linked on its page. The link below earns us nothing.
Straight answers
NovoCare Pharmacy vs Hims, in short
- Is NovoCare Pharmacy or Hims cheaper?
- Neither. Both advertise the same starting price, $149 a month. What separates them is what that figure covers: NovoCare Pharmacy includes medication, and Hims bills it separately.
- What is the difference between NovoCare Pharmacy and Hims?
- Both supply the same category — FDA-approved medication only — so the differences are price, how the consultation works, and what each one has on its regulatory record.
- Which one has more regulatory actions on record?
- Hims, with 4 sourced actions against 1 action for NovoCare Pharmacy. Every one is linked to its primary document on the provider's own page. A larger file is not automatically a worse company — read what the documents actually say.
Other comparisons: Hims vs Ro (Ro Body) · Hims vs Hers · Hims vs Noom (Noom Med) · Hims vs Calibrate · Hims vs Henry Meds · Hims vs LillyDirect